Kyverna Therapeutics (KYTX) Operating Leases (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Operating Leases came in at $7.0 million in Q1 2026, up 112.13% YoY from $3.3 million in Q1 2025, and up 2074.38% on a QoQ basis from $320000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) Operating Leases (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Operating Leases data on file, last reported at $7.0 million in Q1 2026.
- Quarterly Operating Leases rose 112.13% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 112.13% YoY) and the FY2025 annual result came in at $320000.0, down 92.31% from the prior year.
- Operating Leases rose to $7.0 million in Q1 2026, from $320000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $7.0 million in Q1 2026 to a low of $320000.0 in Q4 2025.
- A 4-year average of $4.1 million and a median of $4.6 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases tumbled 92.31% — and 2026, when it jumped 112.13%.
- Tracing KYTX's Operating Leases over 4 years: stood at $5.2 million in 2023, then dropped by 20.58% to $4.2 million in 2024, then plunged by 92.31% to $320000.0 in 2025, then jumped by 2074.38% to $7.0 million in 2026.
- The last three Operating Leases figures came in at $7.0 million (Q1 2026), $320000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.59 Mn |
| Mar 31, 2026 | 6.96 Mn |
| Dec 31, 2025 | 320,000.00 |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 3.28 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Sep 30, 2024 | 4.97 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 6.46 Mn |
| Dec 31, 2023 | 5.24 Mn |